Your browser doesn't support javascript.
Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient.
Wurm, Hannah; Attfield, Kate; Iversen, Astrid Kn; Gold, Ralf; Fugger, Lars; Haghikia, Aiden.
  • Wurm H; Department of Neurology, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.
  • Attfield K; Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.
  • Iversen AK; Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.
  • Gold R; Department of Neurology, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.
  • Fugger L; Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK/MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.
  • Haghikia A; Department of Neurology, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.
Mult Scler ; 26(10): 1261-1264, 2020 09.
Article in English | MEDLINE | ID: covidwho-696957
ABSTRACT
Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies might help viral clearance, these patients could be at risk of severe complications if infected. Here, we report on an MS patient who had received rituximab for ~3 years. The patient was examined 5 days before the onset of coronavirus disease 2019 (COVID-19) symptoms and was admitted to the hospital 2 days after. She recovered 14 days after symptom onset despite having a 0% B lymphocyte count and not developing SARS-CoV-2 immunoglobulin G (IgG) antibodies.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / B-Lymphocytes / Killer Cells, Natural / CD4-Positive T-Lymphocytes / Coronavirus Infections / Multiple Sclerosis, Chronic Progressive / Rituximab / Immunity, Cellular Type of study: Case report / Prognostic study Topics: Long Covid Limits: Female / Humans / Middle aged Language: English Journal: Mult Scler Journal subject: Neurology Year: 2020 Document Type: Article Affiliation country: 1352458520943791

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / B-Lymphocytes / Killer Cells, Natural / CD4-Positive T-Lymphocytes / Coronavirus Infections / Multiple Sclerosis, Chronic Progressive / Rituximab / Immunity, Cellular Type of study: Case report / Prognostic study Topics: Long Covid Limits: Female / Humans / Middle aged Language: English Journal: Mult Scler Journal subject: Neurology Year: 2020 Document Type: Article Affiliation country: 1352458520943791